🔗 Share this article The Global Health Body Raises Warning Over Critical Scarcity of Weight-Loss Jabs Fewer than one in 10 individuals who could benefit from obesity jabs like Wegovy can access them, caution the World Health Organization as it publishes its initial advice on the medications. Given in excess of 1,000,000,000 people worldwide now obese, it is calling for increased and just access to these injectable treatments. According to estimates, more than two billion are projected to be living with obesity by 2030 without intervention. "The latest guidance recognises that excess weight is a long-term condition that can be addressed with comprehensive and ongoing support," said its chief Tedros Adhanom Ghebreyesus. Substantial prices, insufficient output, and logistical bottlenecks are major hurdles to universal access to the jabs that can help people shift substantial body mass, says the body. GLP-1 Therapy Supply Crisis Even under the current most optimistic scenario, the production of these medications could only cover around 100 million people – under 10% of those who need them, according to the WHO. The guideline urges countries and companies to expand access, through strategies such as patent sharing. A patent on a key compound – the core component of the drug Wegovy – is due to expire in a number of countries in 2026. The Way Obesity Injections Work The injections replicate a biological compound to reduce digestion speed, reduce hunger and increase the sense of being full so individuals eat less. Patients typically see weight reduction in the initial weeks of starting on the once-weekly jabs. Studies points to people may see weight return a year later of discontinuing the drug, when their usual hunger return. To be overweight or obese raises your chance for contracting diseases, such as type 2 diabetes, heart disease, brain attack, and specific cancers. Obesity impacts individuals in all nations and was responsible for millions of fatalities worldwide in 2024, per the WHO.
Fewer than one in 10 individuals who could benefit from obesity jabs like Wegovy can access them, caution the World Health Organization as it publishes its initial advice on the medications. Given in excess of 1,000,000,000 people worldwide now obese, it is calling for increased and just access to these injectable treatments. According to estimates, more than two billion are projected to be living with obesity by 2030 without intervention. "The latest guidance recognises that excess weight is a long-term condition that can be addressed with comprehensive and ongoing support," said its chief Tedros Adhanom Ghebreyesus. Substantial prices, insufficient output, and logistical bottlenecks are major hurdles to universal access to the jabs that can help people shift substantial body mass, says the body. GLP-1 Therapy Supply Crisis Even under the current most optimistic scenario, the production of these medications could only cover around 100 million people – under 10% of those who need them, according to the WHO. The guideline urges countries and companies to expand access, through strategies such as patent sharing. A patent on a key compound – the core component of the drug Wegovy – is due to expire in a number of countries in 2026. The Way Obesity Injections Work The injections replicate a biological compound to reduce digestion speed, reduce hunger and increase the sense of being full so individuals eat less. Patients typically see weight reduction in the initial weeks of starting on the once-weekly jabs. Studies points to people may see weight return a year later of discontinuing the drug, when their usual hunger return. To be overweight or obese raises your chance for contracting diseases, such as type 2 diabetes, heart disease, brain attack, and specific cancers. Obesity impacts individuals in all nations and was responsible for millions of fatalities worldwide in 2024, per the WHO.